Clinical Trial

Clindamycin as Antimicrobial Treatment for Streptococcus Spp. PeRiprosthetic Infection

Study acronym: CASPR
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 13, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
Clindamycin is an antibiotic with several advantages: high oral bioavailability and good bone and joint penetration. In France, it is a recommended drug for other types of Streptococcus spp. osteoarticular infections and can be used as an alternative to amoxicillin for periprosthetic infections, including when implants are retained. The hypothesis of this study is that clindamycin is no less effective than other drugs commonly used to treat periprosthetic Streptococcus spp. infections. The primary objective of this study is to evaluate the success rate of Streptococcus spp. periprosthetic joint infections treated with clindamycin compared to other antibiotic treatments.
Trial Details
NCT Number NCT07335627
Lead Sponsor University Hospital, Strasbourg, France
Conditions Streptococcus Infection
Enrollment 260 participants
Start Date 2025-02-21
Primary Completion 2026-07 (estimated)
Study Completion 2026-07-21 (estimated)
Updated on ClinicalTrials.gov 2026-01-13